title: Eyelash trichomegaly following treatment with erlotinib in a non-small cell lung cancer patient: A case report and literature review.
abstract: Inhibitors of epidermal growth factor receptor (EGFR), including tyrosine kinase inhibitors (TKIs), present significant clinical benefits in the treatment of non-small cell lung cancer (NSCLC), particularly in patients with an EGFR mutation. However, TKI treatment also results in unwanted cutaneous toxic side effects, such as a skin rash. Eyelash trichomegaly is rarely reported as a side effect; however, it causes cosmetic issues or eyeball irritation in patients, which may result in the early termination of TKI treatment. Therefore, although TKI-induced eyelash trichomegaly is rare, it should be considered carefully by lung cancer physicians. The present study reported a case of erlotinib-induced eyelash trichomegaly in a 65-year-old Chinese female patient suffering from NSCLC with an EGFR mutation. To the best of our knowledge, this is the first reported case of erlotinib-induced trichomegaly in a Chinese patient.
authors.affiliation: Department of Oncology, The Second People's Hospital of Yibin, Yibin, Sichuan 644000, P.R. China.
authors.forename: Shan-Bing
authors.initials: SB
authors.lastname: Wang
authors.affiliation: Department of Oncology, The Second People's Hospital of Yibin, Yibin, Sichuan 644000, P.R. China.
authors.forename: Kai-Jian
authors.initials: KJ
authors.lastname: Lei
authors.affiliation: Department of Laboratory Medicine, The Second People's Hospital of Yibin, Yibin, Sichuan 644000, P.R. China.
authors.forename: Jia-Pei
authors.initials: JP
authors.lastname: Liu
authors.affiliation: Department of Oncology, The Second People's Hospital of Yibin, Yibin, Sichuan 644000, P.R. China.
authors.forename: Yu-Ming
authors.initials: YM
authors.lastname: Jia
keywords: epidermal growth factor receptor; erlotinib; eyelash trichomegaly; non-small cell lung cancer; tyrosine kinase inhibitor